Monomethyl Auristatin F (MMAF), CAS: 745017-94-1, is a potent microtubule inhibitor commonly used in creating antibody-drug conjugates (ADCs) for targeted cancer treatments. As a synthetic derivative of dolastatin 10, MMAF works by disrupting the microtubules—key structural components within cells. This interference halts the cell division process and leads to apoptosis (programmed cell death) specifically in cancer cells, making it a highly effective treatment.
In ADCs, MMAF is attached to a monoclonal antibody that targets cancer cells. Once the ADC binds to a specific antigen on the surface of the cancer cell, the drug is taken into the cell, where MMAF is released to deliver its cytotoxic effects. This targeted delivery ensures that the cytotoxic activity is directed primarily at cancer cells, reducing the harmful side effects often associated with traditional chemotherapy. As a result, MMAF has become a key tool in developing modern cancer therapies that aim to be both effective and safer for patients.
Some of the key advantages of MMAF in ADCs include:
- Potent cytotoxicity: MMAF blocks tubulin polymerization, halting cell division and killing cancer cells.
- Targeted cancer therapy: By linking MMAF to monoclonal antibodies, researchers can ensure that the cytotoxic drug is delivered directly to cancer cells, leaving healthy cells largely unaffected.
- Proven efficacy: MMAF is used in several FDA-approved ADCs, including Blenrep for multiple myeloma and Polivy for diffuse large B-cell lymphoma (DLBCL).
Why MMAF is Crucial in ADCs
The specific targeting and potent cytotoxic action of MMAF make it an indispensable tool in the development of ADCs. Its ability to kill cancer cells while minimizing toxicity to normal tissues has revolutionized cancer treatment, providing patients with more effective and safer options.
In summary, MMAF plays a pivotal role in targeted cancer therapies, offering a combination of powerful anti-cancer activity and reduced side effects. This makes MMAF-based ADCs a cornerstone in the ongoing fight against various types of cancer.
Ref:
Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PY. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol Cancer Ther June 2006 5; 1474-82.
Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel). 2011;3(7):848-883.
Monomethyl auristatin E (Wikipedia)
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
